PriceTargets.com logo

NASDAQ:OGI - OrganiGram Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $4.29
  • Forecasted Upside: 78.57 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.40 As of 09/17/2021 01:00 AM ET
+0.30 (1.20%)

This chart shows the closing price for OGI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OrganiGram Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OGI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OGI

Analyst Price Target is $4.29
▲ +78.57% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for OrganiGram in the last 3 months. The average price target is $4.29, with a high forecast of $6.00 and a low forecast of $3.50. The average price target represents a 78.57% upside from the last price of $2.40.

This chart shows the closing price for OGI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 8 contributing investment analysts is to hold stock in OrganiGram. This rating has held steady since December 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 10 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
8/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/23/2021Atb Cap MarketsReiterated RatingSector PerformHigh
7/15/2021Stifel NicolausLower Price TargetHoldC$4.00 ➝ C$3.75Low
7/14/2021CIBCBoost Price TargetNeutralC$3.75 ➝ C$4.00Low
7/9/2021CIBCReiterated RatingHold$3.75Low
6/11/2021CIBCBoost Price TargetNeutralC$3.25 ➝ C$3.75Medium
5/11/2021CIBCUpgradeSector Underperform ➝ NeutralHigh
4/20/2021CIBCReiterated RatingNeutral ➝ Underperformer$5.00 ➝ $3.25High
4/15/2021Stifel NicolausBoost Price TargetHold$4.00 ➝ $6.00Medium
4/14/2021Raymond JamesLower Price TargetOutperform$6.00 ➝ $5.00Medium
4/14/2021Canaccord GenuityBoost Price TargetHold$2.00 ➝ $3.50High
4/14/2021CIBCDowngradeNeutral ➝ Sector Underperform$5.00 ➝ $3.25High
4/13/2021Alliance Global PartnersLower Price TargetNeutral$4.00 ➝ $3.75High
4/8/2021BMO Capital MarketsUpgradeUnderperform ➝ Market Perform$4.00Medium
3/16/2021Stifel NicolausBoost Price TargetHold$1.90 ➝ $6.00Low
3/16/2021BMO Capital MarketsReiterated RatingMarket Perform ➝ Underperform$2.00High
3/12/2021CIBCBoost Price TargetNeutral$4.25 ➝ $5.00Low
3/12/2021Raymond JamesBoost Price TargetOutperform$3.00 ➝ $6.00Low
3/11/2021Cantor FitzgeraldReiterated RatingOverweight$3.50 ➝ $6.00High
3/11/2021Alliance Global PartnersReiterated RatingNeutralHigh
3/10/2021BMO Capital MarketsDowngradeMarket Perform ➝ Underperform$2.00High
2/22/2021CIBCBoost Price TargetNeutral$2.25 ➝ $4.25High
1/13/2021Alliance Global PartnersDowngradeBuy ➝ NeutralMedium
1/12/2021Canaccord GenuityDowngradeBuy ➝ Hold$2.50 ➝ $2.00High
1/12/2021Raymond JamesUpgradeMarket Perform ➝ OutperformHigh
12/4/2020Cantor FitzgeraldLower Price TargetOverweight$5.35 ➝ $3.00High
12/1/2020CIBCBoost Price TargetNeutral$2.00 ➝ $2.25High
12/1/2020Canaccord GenuityReiterated RatingBuyHigh
9/17/2020Cantor FitzgeraldReiterated RatingBuy$5.35Medium
8/10/2020Jefferies Financial GroupReiterated RatingBuy$3.79High
7/22/2020CIBCLower Price TargetNeutral$2.75 ➝ $2.00High
7/22/2020Canaccord GenuityLower Price TargetBuy$5.00 ➝ $3.00Low
7/22/2020Stifel NicolausDowngradeBuy ➝ Hold$1.75Medium
7/21/2020Pi FinancialReiterated RatingBuyMedium
7/21/2020AltaCorp CapitalDowngradeOutperform ➝ Sector PerformHigh
7/21/2020OppenheimerReiterated RatingHoldHigh
7/7/2020Alliance Global PartnersInitiated CoverageBuy$4.00Medium
6/29/2020Raymond JamesDowngradeOutperform ➝ Market PerformMedium
6/16/2020OppenheimerInitiated CoverageHoldMedium
5/29/2020Raymond JamesReiterated RatingBuyMedium
4/15/2020CIBCDowngradeOutperform ➝ Neutral$5.00 ➝ $2.75Low
4/14/2020AltaCorp CapitalUpgradeSector Perform ➝ OutperformLow
4/14/2020Cantor FitzgeraldLower Price TargetOverweight$5.80 ➝ $5.60Low
4/1/2020Cantor FitzgeraldLower Price TargetOverweight$9.00 ➝ $5.80High
3/19/2020Bank of AmericaUpgradeHold$1.72High
3/19/2020CitigroupUpgradeUnderperform ➝ NeutralMedium
1/15/2020Raymond JamesUpgradeMarket Perform ➝ OutperformHigh
1/13/2020Bank of AmericaInitiated CoverageUnderperformHigh
1/8/2020Raymond JamesDowngradeOutperform ➝ Market PerformLow
11/26/2019AltaCorp CapitalDowngradeOutperform ➝ Sector PerformLow
11/25/2019Beacon SecuritiesDowngradeBuy ➝ HoldHigh
11/12/2019BMO Capital MarketsDowngradeOutperform ➝ Market PerformHigh
11/5/2019Cantor FitzgeraldInitiated CoverageOverweight$17.10High
10/17/2019Paradigm CapitalSet Price TargetBuy$8.50Low
10/11/2019Jefferies Financial GroupUpgradeHold ➝ Buy$8.20High
9/24/2019CIBCInitiated CoverageOutperformer$9.00High
9/18/2019Raymond JamesInitiated CoverageBuyLow
9/5/2019OppenheimerInitiated CoverageMarket PerformHigh
7/15/2019Pi FinancialSet Price TargetBuy$12.00High
5/3/2019Jefferies Financial GroupDowngradeBuy ➝ HoldLow
4/17/2019Paradigm CapitalInitiated CoverageBuyLow
2/25/2019Jefferies Financial GroupInitiated CoverageBuyLow
(Data available from 9/20/2016 forward)

News Sentiment Rating

0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
2/22/2021
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/23/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/22/2021
  • 2 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/22/2021
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2021
  • 4 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2021

Current Sentiment

  • 4 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

OrganiGram logo
OrganiGram Holdings, Inc. engages in the production and sale of medical marijuana. It focuses on producing cannabis for patients and adult recreational consumers. The firm's brands include Adult Recreational and Medical. The company was founded on July 5, 2010 and is headquartered in Moncton, Canada.
Read More

Today's Range

Now: $2.40
Low: $2.35
High: $2.46

50 Day Range

MA: $2.58
Low: $2.35
High: $2.94

52 Week Range

Now: $2.40
Low: $1.01
High: $6.45

Volume

6,412,900 shs

Average Volume

13,357,594 shs

Market Capitalization

$719.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.1

Frequently Asked Questions

What sell-side analysts currently cover shares of OrganiGram?

The following Wall Street sell-side analysts have issued reports on OrganiGram in the last twelve months: Alliance Global Partners, Atb Cap Markets, BMO Capital Markets, Canaccord Genuity, Cantor Fitzgerald, CIBC, Raymond James, Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for OGI.

What is the current price target for OrganiGram?

7 Wall Street analysts have set twelve-month price targets for OrganiGram in the last year. Their average twelve-month price target is $4.29, suggesting a possible upside of 78.6%. Cantor Fitzgerald has the highest price target set, predicting OGI will reach $6.00 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $3.50 for OrganiGram in the next year.
View the latest price targets for OGI.

What is the current consensus analyst rating for OrganiGram?

OrganiGram currently has 6 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in OGI, but not buy more shares or sell existing shares.
View the latest ratings for OGI.

What other companies compete with OrganiGram?

Other companies that are similar to OrganiGram include Verve Therapeutics, Cytokinetics, Lyell Immunopharma, Intra-Cellular Therapies, Agios Pharmaceuticals, Sage Therapeutics, Aurinia Pharmaceuticals, OPKO Health, ACADIA Pharmaceuticals, Prestige Consumer Healthcare, Pacira BioSciences, Morphic, Taro Pharmaceutical Industries, Ligand Pharmaceuticals and IGM Biosciences.

How do I contact OrganiGram's investor relations team?

OrganiGram's physical mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company's listed phone number is (844) 644-4726. The official website for OrganiGram is www.organigram.ca.